Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 26 January 1990:
Vol. 247. no. 4941, pp. 454 - 456
DOI: 10.1126/science.2405486
Prev | Table of Contents | Next

Articles

Science, Vol 247, Issue 4941, 454-456
Copyright © 1990 by American Association for the Advancement of Science

articles

A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation

TJ McQuade, AG Tomasselli, L Liu, V Karacostas, B Moss, TK Sawyer, RL Heinrikson, and WG Tarpley

Infectious Disease Research Unit, Upjohn Company, Kalamazoo, MI 49001.

A synthetic peptidemimetic substrate of the human immunodeficiency virus 1 (HIV-1) protease with a nonhydrolyzable pseudodipeptidyl insert at the protease cleavage site was prepared. The peptide U-81749 inhibited recombinant HIV-1 protease in vitro (inhibition constant Ki of 70 nanomolar) and HIV-1 replication in human peripheral blood lymphocytes (inhibitory concentration IC50 of 0.1 to 1 micromolar). Moreover, 10 micromolar concentrations of U-81749 significantly inhibited proteolysis of the HIV-1 gag polyprotein (p55) to the mature viral structural proteins p24 and p17 in cells infected with a recombinant vaccinia virus expressing the HIV-1 gag-pol genes. The HIV-1 like particles released from inhibitor-treated cells contained almost exclusively p55 and other gag precursors, but not p24. Incubation of HIV-like particles recovered from drug-treated cultures in drug-free medium indicated that inhibition of p55 proteolysis was at least partially reversible, suggesting that U-81749 was present within the particles.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Coupling of Human Immunodeficiency Virus Type 1 Fusion to Virion Maturation: a Novel Role of the gp41 Cytoplasmic Tail.
D. J. Wyma, J. Jiang, J. Shi, J. Zhou, J. E. Lineberger, M. D. Miller, and C. Aiken (2004)
J. Virol. 78, 3429-3435
   Abstract »    Full Text »    PDF »
Reversal by Dithiothreitol Treatment of the Block in Murine Leukemia Virus Maturation Induced by Disulfide Cross-Linking.
S. Campbell, M. Oshima, J. Mirro, K. Nagashima, and A. Rein (2002)
J. Virol. 76, 10050-10055
   Abstract »    Full Text »    PDF »
Effects of Antiretroviral Drugs on Human Immunodeficiency Virus Type 1-Induced CD4+ T-Cell Death.
J. Estaquier, J.-D. Lelievre, F. Petit, T. Brunner, L. Moutouh-de Parseval, D. D. Richman, J. C. Ameisen, and J. Corbeil (2002)
J. Virol. 76, 5966-5973
   Abstract »    Full Text »    PDF »
Conserved Cysteines of the Human Immunodeficiency Virus Type 1 Protease Are Involved in Regulation of Polyprotein Processing and Viral Maturation of Immature Virions.
D. A. Davis, K. Yusa, L. A. Gillim, F. M. Newcomb, H. Mitsuya, and R. Yarchoan (1999)
J. Virol. 73, 1156-1164
   Abstract »    Full Text »
Constrained Evolution of Human Immunodeficiency Virus Type 1 Protease during Sequential Therapy with Two Distinct Protease Inhibitors.
A. Dulioust, S. Paulous, L. Guillemot, A.-M. Delavalle, F. Boue, and F. Clavel (1999)
J. Virol. 73, 850-854
   Abstract »    Full Text »    PDF »
Resistance-Associated Loss of Viral Fitness in Human Immunodeficiency Virus Type 1: Phenotypic Analysis of Protease and gag Coevolution in Protease Inhibitor-Treated Patients.
F. Mammano, C. Petit, and F. Clavel (1998)
J. Virol. 72, 7632-7637
   Abstract »    Full Text »    PDF »
Cell Cycle Arrest by Vpr in HIV-1 Virions and Insensitivity to Antiretroviral Agents.
B. Poon, K. Grovit-Ferbas, S. A. Stewart, and I. S. Chen (1998)
Science 281, 266-269
   Abstract »    Full Text »
Human Immunodeficiency Virus Type 1 Protease Inhibitors.
C. K. McDonald and D. R. Kuritzkes (1997)
Arch Intern Med 157, 951-959
   Abstract »    PDF »
HIV-1 Protease Inhibitors: A Review for Clinicians.
S. G. Deeks, M. Smith, M. Holodniy, and J. O. Kahn (1997)
JAMA 277, 145-153
   Abstract »    PDF »
Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine.
A. C. Collier, R. W. Coombs, D. A. Schoenfeld, R. L. Bassett, J. Timpone, A. Baruch, M. Jones, K. Facey, C. Whitacre, V. J. McAuliffe, et al. (1996)
N. Engl. J. Med. 334, 1011-1018
   Abstract »    Full Text »    PDF »
Present status and future prospects for HIV therapies.
M. Johnston and D. Hoth (1993)
Science 260, 1286-1293
   Abstract »    PDF »
Antiretroviral Chemotherapy of Human Immunodeficiency Virus Infections Other Than With Azidothymidine.
M. K. Sachs (1992)
Arch Intern Med 152, 485-501
   Abstract »    PDF »
Antiretroviral Therapy in AIDS.
S. Broder, H. Mitsuya, R. Yarchoan, and G. N. Pavlakis (1990)
Ann Intern Med 113, 604-618
   Abstract »    PDF »
Molecular targets for AIDS therapy.
H Mitsuya, R Yarchoan, and S Broder (1990)
Science 249, 1533-1544
   Abstract »    PDF »
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.
J Erickson, D. Neidhart, J VanDrie, D. Kempf, X. Wang, D. Norbeck, J. Plattner, J. Rittenhouse, M Turon, N Wideburg, et al. (1990)
Science 249, 527-533
   Abstract »    PDF »
Rational design of peptide-based HIV proteinase inhibitors.
N. Roberts, J. Martin, D Kinchington, A. Broadhurst, J. Craig, I. Duncan, S. Galpin, B. Handa, J Kay, A Krohn, et al. (1990)
Science 248, 358-361
   Abstract »    PDF »
Isolation of peptide aptamers that inhibit intracellular processes.
J. H. Blum, S. L. Dove, A. Hochschild, and J. J. Mekalanos (2000)
PNAS 97, 2241-2246
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)